Tackling Obesity with New FDA-Approved Drug Zepbound
New Era in Weight Management with Tirzepatide-Based Treatment
Pharmacological treatments against obesity represent hope and, at the same time, a reality to treat and, in some cases, cure this serious disease and many others.
The medication Zepbound was approved today by the FDA, which has marked a new advance in the fight against obesity. This medication, which is expected to be available in the United States by the end of the year, contains tirzepatide, an active ingredient also present in Mounjaro, a diabetes treatment.
Tirzepatide, the active substance in Zepbound, slows stomach emptying, making people feel full more quickly and for extended periods. The medication acts on the area of the brain that controls appetite, helping to reduce uncontrollable desires to eat.
In recent years, Ozempic and Wegovy have been very popular; they work to improve the health of patients with type 2 diabetes and for weight loss. It has also meant an economic boom for Novo Nordisk company and its country of origin, Denmark.
